Does wegovy (semaglutide) effect bone density or bone strength?
- AJ Hill Aesthetics
- 10 hours ago
- 5 min read
And does it increase our risk of fractures?
Well... the short answer is no. And here's why.
Current evidence does not suggest that semaglutide (Wegovy/Ozempic/Rybelsus) directly weakens bone or increases fracture risk. However, rapid weight loss, inadequate nutrition, loss of muscle mass, and reduced mechanical loading of the skeleton during treatment can indirectly contribute to bone loss in some people, particularly those already at risk of osteoporosis. The medication itself may not be the main concern—the physiological consequences of substantial weight loss appear to be.
Does semaglutide directly affect bone?
At present, there is no convincing clinical evidence that semaglutide has a toxic effect on bone cells.
In fact, laboratory research suggests GLP-1 receptors are present on:
osteoblasts (bone-forming cells)
osteoclasts (bone-resorbing cells)
bone marrow stem cells
Experimental studies suggest GLP-1 signalling may actually:
reduce bone resorption
promote bone formation
reduce inflammation within bone
improve bone quality
This has led researchers to believe GLP-1 receptor agonists could theoretically protect bone, although translating animal findings into humans has proved more complex.
What do clinical trials show?
The highest-quality evidence currently comes from systematic reviews and meta-analyses of randomised controlled trials.
A 2025 meta-analysis including 25 clinical studies found:
no increase in fracture risk
small improvements in lumbar spine bone mineral density
improvements in hip bone density
reductions in bone turnover markers associated with bone loss
improvements in several markers of bone formation and vitamin D status
The authors concluded there was no evidence that GLP-1 receptor agonists increase fracture risk, although they noted that longer-term studies are still needed.
A larger 2025 network meta-analysis including over 33,000 patients reached similar conclusions, reporting improvements in bone mineral density at the lumbar spine, femoral neck and total hip without evidence of excess fractures.
Then why are people still concerned?
Weight loss itself can directly effect our bone density and bone strength. Here's the why and the how:
Weight loss impacting bone density and strength has been recognised for decades—even after:
bariatric surgery
very-low-calorie diets
cancer-related weight loss
frailty in older adults
This is because bone is living tissue.
It constantly remodels according to:
body weight
muscle forces
nutrition
hormones
When someone loses 15–25 kg, several things happen simultaneously.
1. Reduced mechanical loading
Bone adapts to the weight it carries.
A heavier skeleton requires stronger bones. When body weight falls substantially:
hips experience less loading
knees experience less loading
vertebrae experience less loading
This reduces the stimulus for maintaining bone mass.
This occurs regardless of how the weight is lost.
2. Lower protein intake
Many people taking Wegovy struggle to consume enough protein because appetite is greatly reduced.
Protein is essential for:
collagen synthesis
bone matrix formation
muscle maintenance
Poor protein intake is associated with:
lower bone mineral density
increased fracture risk
slower healing after fractures.
3. Calcium deficiency
Reduced food intake often means reduced calcium intake.
If calcium intake becomes inadequate, the body maintains blood calcium by increasing bone resorption.
Over months or years this can reduce bone density.
4. Vitamin D deficiency
Vitamin D deficiency is already common in the UK.
If patients eat less of:
oily fish
dairy
fortified foods
, then their Vitamin D intake may worsen. Vitamin D deficiency reduces calcium absorption and accelerates bone loss.
5. Loss of muscle mass
One of the biggest concerns surrounding GLP-1 medications is loss of lean body mass.
Approximately 20–40% of weight lost during treatment may come from lean tissue, including muscle, although the proportion varies depending on diet and exercise.
Muscle protects bone by:
generating mechanical loading
improving balance
preventing falls
stimulating bone formation
Loss of muscle therefore increases fracture risk indirectly.
6. Reduced exercise
Some people feel:
tired
weak
less energetic
particularly early in treatment.
If resistance exercise stops:
muscle declines
bone stimulation decreases
falls become more likely.
So... could semaglutide actually protect bone?
"Maybe" is the best answer. Some researchers believe two opposing mechanisms are occurring simultaneously.
Potential protective effects
reduced inflammation
improved diabetes control
improved osteoblast activity
reduced osteoclast activity
versus
Potential harmful effects
rapid weight loss
lower protein intake
calcium deficiency
vitamin D deficiency
muscle loss
reduced skeletal loading
The net effect probably depends on the individual patient.
Does fracture risk increase?
Current randomised trial evidence says no significant increase.
The 2025 systematic review found:
fracture risk ratio = 0.80
confidence interval crossed 1
therefore not statistically significant
In other words, fractures were not more common in patients receiving GLP-1 receptor agonists than in control groups.
Another large network meta-analysis also found that GLP-1 receptor agonists were not associated with higher fracture risk and, in some analyses, appeared to reduce fractures compared with other diabetes treatments.
Why are headlines suggesting osteoporosis?
Earlier this year, a large observational study presented at the American Academy of Orthopaedic Surgeons reported an association between long-term GLP-1 use and higher rates of osteoporosis and osteomalacia.
However, this study has important limitations:
it was observational rather than a randomised trial
it cannot prove the medication caused the findings
residual confounding is likely (for example, people taking GLP-1 drugs may lose more weight or differ in other ways from those who do not)
details such as nutritional intake, exercise, and degree of weight loss were not fully captured.
As a result, most experts view these findings as a signal for further research rather than evidence that semaglutide directly harms bone.
Who may be at higher risk?
Extra attention should be paid to:
adults over 65
postmenopausal women
people with existing osteoporosis
long-term corticosteroid users
patients with previous fragility fractures
people with low BMI
patients losing weight very rapidly (>1 kg/week for prolonged periods)
those consuming very low-calorie diets
people with poor protein intake
individuals with vitamin D deficiency.
How can bone health be protected during semaglutide treatment?
Current expert recommendations include:
Aim for 1.0–1.5 g of protein per kilogram of target or adjusted body weight per day (individual needs vary).
Ensure an adequate calcium intake (around 700 mg/day for most UK adults, with higher requirements in some situations).
Maintain sufficient vitamin D through safe sun exposure, diet, or supplementation where appropriate (many UK adults require supplementation, especially in winter).
Perform resistance training at least 2–3 times per week.
Include regular weight-bearing exercise such as walking, stair climbing, or jogging if medically appropriate.
Avoid very rapid weight loss where possible.
In higher-risk individuals, clinicians may consider baseline and follow-up bone mineral density (DXA) scans.
conclusion
The current evidence is reassuring: semaglutide does not appear to directly reduce bone density or increase fracture risk, and some studies even suggest modest improvements in bone mineral density and bone turnover markers.
That said, rapid weight loss itself can adversely affect bone health. Reduced food intake, inadequate protein, calcium or vitamin D, loss of muscle mass, and decreased mechanical loading of the skeleton are all recognised mechanisms that may contribute to bone loss over time. These indirect effects are likely to be most important in older adults, postmenopausal women, or anyone with existing osteoporosis or nutritional deficiencies.
For most adults using Wegovy under appropriate medical supervision, the benefits of achieving and maintaining a healthier weight are likely to outweigh any potential skeletal risks.
Nevertheless, preserving bone health should be considered part of good obesity care through adequate nutrition, resistance exercise, and appropriate monitoring in people at increased risk.
